BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064950
CREATED:20230405T225751Z
LAST-MODIFIED:20230405T225751Z
UID:37019-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:ADC Toxicity Summit
DESCRIPTION:There is a vast number of ADCs that never make it to the clinic let alone to market\, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity\, their translatability into the clinic\, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. \nThe inaugural ADC Toxicity Summit is coming to Boston\, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action\, discuss shared challenges associated with translating in vivo toxicity data to the clinic\, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market. \nTake a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit. \nUniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists\, through to nonclinical\, translational\, and clinical experts\, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients. \n3 reasons why you can’t miss out on joining include: \n\nSelect optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie\nHear how companies with commercially approved ADCs mitigated toxicities in the clinic\, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute\nUncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb\, Iksuda and Merck & Co\n\nHarnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies\, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release\, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.
URL:https://www.pharmajournalist.com/event/adc-toxicity-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064950
CREATED:20230516T104255Z
LAST-MODIFIED:20230516T104255Z
UID:37192-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:2nd Annual Targeted Radiopharmaceuticals Summit
DESCRIPTION:With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer\, the TRP space is continuing to go from strength to strength. \nThis is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever\, bringing you a tracked agenda covering the whole TRP landscape from discovery\, translation\, to clinical\, late stage progress and challenges – a unique opportunity for your entire team to learn and network. \nJoin us to: \n\nExplore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic\nNavigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals\nReview theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs\nDiscover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities\nHarness the platform technologies for optimized preclinical evaluation of drugs\n\nAll presented by top industry players such as Clarity Pharmaceuticals\, SOFIE Biosciences\, Lantheus\, Fusion Pharmaceuticals\, Rayze Bio\, Telix Pharmaceuticals\, OranoMed\, Actinium Pharmaceuticals\, and many more. \nDownload the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2
URL:https://www.pharmajournalist.com/event/2nd-annual-targeted-radiopharmaceuticals-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064950
CREATED:20230601T114828Z
LAST-MODIFIED:20230601T114828Z
UID:37256-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:Fusion Protein Engineering & Developability Summit
DESCRIPTION:Design & Engineer Functional & Manufacturable Novel Fusion Proteins \nPrepare to be captivated by the Fusion Protein Engineering & Developability Summit\, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list! \nAs the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets\, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche\, Merck\, Bristol Myers Squibb\, Abbvie\, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers\, exchange innovative ideas and strategies\, and gain invaluable insights into cutting-edge fusion applications. \nPrepare for a whirlwind of activity across the action-packed three-day agenda\, including: \n\nCutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering\, encompassing the most recent research and emerging trends in this dynamic field.\nPractical Learning: Immerse yourself in hands-on workshops led by industry experts\, designed to enhance your skills and knowledge in must-know areas.\nReal-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers\, offering profound insights and best practices.\nEngaging Discussions: Engage in lively panel discussions and roundtable sessions\, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.\nNetworking Opportunities: Forge valuable connections with 60+ protein engineers\, therapeutic developers\, and influential industry leaders during 7+ hours of dedicated networking\, including the renowned speed networking session.\n\nWith a stellar lineup of 25+ speakers\, 3 immersive hands-on workshops\, and 2 days packed with data-driven case studies\, this event is set to become the unequivocal highlight of the year and you cannot afford to miss it! \nTo know more visit: https://ter.li/uuyrdu
URL:https://www.pharmajournalist.com/event/fusion-protein-engineering-developability-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064950
CREATED:20230608T113503Z
LAST-MODIFIED:20230608T113503Z
UID:37317-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:4th Gamma Delta T Therapies Summit
DESCRIPTION:Established industry leaders and emerging innovators such as Adicet Bio\, IN8Bio\, Sanofi\, Merck\, LAVA Therapeutics\, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic\, off-the-shelf solid tumor therapies\, spurred by early indications of clinical efficacy. \nThe 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research\, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day\, building on early clinical successes\, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic. \nTo know more visit: https://ter.li/69o2yc
URL:https://www.pharmajournalist.com/event/4th-gamma-delta-t-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR